title: Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.
abstract: OBJECTIVE
  This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies.
  
  
  METHODS
  The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3).
  
  
  RESULTS
  The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 µm (± 35.7) at baseline to 274.57 µm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 µm (± 100.4) to 339.56 µm (± 145.3) (p=0.184) in Group 2; and from 259.18 µm (± 97.9) to 282.21 µm (± 87.24) (p=0.044) in Group 3.
  
  
  CONCLUSIONS
  Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy.
authors: Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain.
authors: Roberto
authors: R
authors: Gallego-Pinazo
authors: Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain.
authors: Rosa
authors: R
authors: Dolz-Marco
authors: Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico.
authors: Maria
authors: M
authors: Berrocal
authors: Instituto de Cirugía Ocular, San Jose, Costa Rica.
authors: Lihteh
authors: L
authors: Wu
authors: Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
authors: Mauricio
authors: M
authors: Maia
authors: Clinica Oftalmologica Centro Caracas, Caracas, Venezuela.
authors: Martín
authors: M
authors: Serrano
authors: Cátedra de Oftalmologia, Universidad de Buenos Aires, Buenos Aires, Argentina.
authors: Arturo
authors: A
authors: Alezzandrini
authors: Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
authors: J Fernando
authors: JF
authors: Arévalo
authors: Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain.
authors: Manuel
authors: M
authors: Díaz-Llopis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002386:Cataract / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003930:Diabetic Retinopathy / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007430:Intraoperative Care; D058449:Intravitreal Injections; D019654:Lens Implantation, Intraocular / Q000379:methods*; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000379:methods*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014221:Triamcinolone / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D014221:Triamcinolone; D000068258:Bevacizumab